Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at

Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at
LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced that results from an ongoing Phase II clinical trial of Puma's investigational drug PB272 (neratinib) were presented at …
Read more on Business Wire (press release)

Team develops innovative gene-silencing biotechnology to advance
Ben-Gurion University of the Negev (BGU) has developed an advanced gene-silencing biotechnology for aquaculture that changes the sex of prawns and yields the faster-growing all male populations, resulting in greater output and farmer income.
Read more on Phys.Org

Leave a Reply